Caremo Completes Tens of Millions RMB Series B1 Financing Round ！

August 26, 2025, Nanjing, China – Caremo announced the completion of a Series B1 financing round raising tens of millions of RMB. This round was jointly invested by the Lianyungang Industrial Investment Fund and existing shareholder Bondshine Capital. The funds will be used for the development of Caremo's innovative businesses and the construction of its R&D platform. This financing round marks a new milestone, following the completion of a 150 million RMB Series A round in June 2022 and a 100 million RMB Series A+ round in April 2023. Securing this investment amidst the current challenging and highly competitive pharmaceutical industry landscape highlights the high recognition from investment institutions for Caremo's growth potential, resilience, development prospects, and market competitiveness. This infusion of capital will provide strong momentum for the company's development. We are confident in working together with all investors towards a new era of mutual success and win-win collaboration.

Caremo provides partners with one-stop, customizable solutions and full-process project management, covering the entire product lifecycle from initiation to commercialization, enabling efficient and rapid support for partners in advancing their drug development processes. Caremo has assembled an R&D management team of over 500 members with extensive experience in preclinical research and CMC (Chemistry, Manufacturing, and Controls). The company operates over 35,000 square meters of CMC, chemical, and GLP laboratories compliant with Chinese and US regulatory requirements, equipped with instrument assets valued at over 200 million RMB. Caremo has been honored with numerous awards and recognitions, including "National High-Tech Enterprise," "Science and Technology-Based SME," "Jiangsu Provincial Private Sci-Tech Enterprise," "2025 Top 20 Chinese Drug Formulation CROs," "2023 & 2024 Jiangsu Potential Unicorn Enterprise," "Nanjing Engineering Technology Research Center for Special Dosage Form Drugs," "Nanjing Engineering Research Center for Local Transdermal Drug Delivery Systems," "2024 Top 20 Chinese Pharmaceutical CRO Enterprises," "2023-2024 Top 50 Pharmaceutical R&D Companies," "2023 Top 20 Chinese Pharmaceutical CRO Enterprises," "2023 China's Most Competitive Pharmaceutical Service Enterprise," "2022-2023 Top 50 Chinese Pharmaceutical R&D Enterprises," "2022 Best Preclinical CRO/CDMO Enterprise (Emerging Type)." All Caremo laboratories have passed ISO9001 Quality Management System certification.

Dr. Zhang Xiaoqing, Chairman of Caremo Pharma, stated: "Caremo has always adhered to our mission of ‘born for health and empowering for innovation’. Guided by our mission to foster health and empower innovation, Caremo is committed to accelerating the new drug development process and providing partners with high-quality, efficient, seamless integration from preclinical stages to commercialization, jointly witnessing and experiencing the trajectory and rising power of China's new drug development. We continue to uphold a customer-centric mindset, deeply explore data capabilities, integrate technology with business models, and constantly iterate and enhance organizational capabilities. Amidst the current intense competition within the pharmaceutical industry, we sincerely thank the new investors for their firm trust and strong support, our existing shareholders for their continued assistance in the company's development, and all shareholders for their strategic guidance during this critical period! This financing round is not only an affirmation of Caremo's achievements over the past five years but also an expectation for the company's high-quality development in the future. We have come a long way and will continue to forge ahead."

 · About Lianyungang Industrial Investment Fund

Established in 2024 with a fund size of 812.5 million RMB, the Lianyungang Industrial Investment Fund is one of the funds managed by the well-known institution Jolmo Capital. The Industrial Investment Fund is not limited to a single industry and will fully support key provincial and municipal industries and projects, empowering advantaged industries, key enterprises, and "Specialized, Refined, Unique, and New" (SRUN) enterprises. It primarily conducts investments through direct equity investments, leveraging the functional advantages of industrial funds in pooling capital, cultivating industries, and driving innovation to contribute to the construction of the industrial system.

· About Bondshine Capital

Bondshine Capital was established in 2014 following the mixed-ownership reform of Jiangsu High-Tech Investment Group. It is the Vice President Unit of the Jiangsu Fund Industry Association, a Jiangsu Provincial Venture Investment Brand Leader Enterprise, and a Jiangsu Provincial Excellent Venture Investment Team. Bondshine Capital (P1061833) oversees three private investment fund management platforms registered with the Asset Management Association of China (AMAC): Bondshine Capital (P1001650), Coastal Capital (P1014378), and Bondshine Xin Gong (P1061949). Bondshine Capital manages funds encompassing angel funds, venture capital funds, industrial funds, and specialized industry funds, with cumulative assets under management exceeding 10 billion RMB. Bondshine Capital focuses on national strategic emerging industries including information technology, integrated circuits, healthcare, intelligent manufacturing, new energy, new materials, sports culture, and has invested in nearly a hundred projects. It has successfully facilitated the IPO, backdoor listing, or M&A restructuring of over 10 enterprises, including Cambridge Industries Group (ClG), Yueboo, Dingsheng New Energy Materials, LVJI Technology, Sumec, Huarisheng, Ofpay, Guolian MinSheng, S-KING Intelligent, Sunlord, SINOPEP.